Sunday 18 October 2026 Export VTVT’s income statement to Excel — free account

vTv Therapeutics Inc.

In the quarter to June 2026, revenue grew 409,222.2%, EPS fell 14.1% and free cash flow fell 124.6%, each against the same quarter a year earlier.

26.54 1.05 −3.81%

Follow VTVT

Alert me

Market cap: $109.1M
P/E: 0.0×
Fwd P/E: −8.2×
Dividend yield: —
F-score: n/a
Altman Z: −10.00
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 83.40%

Capital & Financial Ratios $m

Market Cap 109.09

Revenue 37.87

Net Income (6.40)

Free Cash Flow (16.76)

Net Debt (86.64)

Current Ratio 12.48

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.15)

P/S ratio 8.71

P/B ratio 4.19

Past 5Y EPS Growth —

This Y EPS Growth 62.25%

Next Y EPS Growth (243.31%)

Next Y revenue growth 293.31%

Next 5Y EPS Growth (12.78%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.20%

10-year low 10-year high

EV/Sales against its own 10 years 19.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	37	89	87
Receivables	0	0	—	—
Inventory	—	—	—	—
Other	0	0	0	1
	11	38	90	88

	2023	2024	2025	Q'26
Payables	10	5	7	7
ST’ Debt	—	—	—	—
Other	0	—	0	0
	11	5	7	7

Compound Annual Growth %

	10y	5y	3y
Sales	0.41%	(39.39%)	(45.88%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	37	—	—	—	—
’24	1	—	—	0	1
’22	2	0	—	0	2
’21	1	0	3	0	4
’20	0	—	0	6	6
’19	1	2	0	0	3
’18	2	2	3	5	12

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(11)	—	—	—
’25	(6)	(5)	(5)	(9)	(25)
’24	(7)	(7)	(6)	(5)	(25)
’23	(5)	(6)	(5)	(3)	(19)
’22	(1)	1	(9)	(7)	(16)
’21	(5)	(4)	(4)	(6)	(19)
’20	(6)	(5)	(5)	(2)	(18)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(11)	—	—	—
’25	(6)	(5)	(5)	(9)	(25)
’24	(7)	(7)	(6)	(5)	(25)
’23	(5)	(6)	(5)	(3)	(19)
’22	(1)	1	(9)	(7)	(16)
’21	(5)	(4)	(4)	(6)	(19)
’20	(6)	(5)	(5)	(2)	(18)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.65	(1.05)	—	—	—
’25	(0.77)	(0.92)	(1.08)	(0.58)	(3.20)
’24	(1.17)	(0.81)	(0.88)	(0.55)	(3.20)
’23	(2.40)	(2.80)	(3.20)	(1.67)	(9.71)
’22	(4.00)	(1.60)	(2.00)	(2.40)	(10.40)
’21	(3.20)	(0.40)	(0.80)	(4.40)	(8.40)
’20	(4.40)	(2.80)	(1.20)	0.80	(7.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	186.00	142.76	26.00	49.20	57.60	36.00	15.28	8.47	7.38	13.20	Analyst estimates 2026–2028 Powerpack
	High	307.20	323.44	336.00	136.00	190.00	151.60	56.00	42.00	30.99	41.49
People
People	Employees	51	56	52	26	25	9	13	16	23	26
	Revenue/emp, $m	0.01	0.01	0.24	0.11	0.26	0.45	0.16	0.00	0.04	0.00
Income, $m
Income, $m	Revenue	1	0	12	3	6	4	2	—	1	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	100.00	—
	EBT	(55)	(54)	(24)	(22)	(13)	(18)	(25)	(26)	(23)	(31)
	EBT margin, %	(8,730.76)	(18,504.12)	(190.16)	(790.09)	(199.59)	(439.85)	(1,232.56)	0.00	(2,222.71)	0.00
	Net income	(55)	(55)	(24)	(22)	(13)	(18)	(25)	(26)	(23)	(31)
	Depreciation	0	1	1	1	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	2.66	1.20	39.96	3.65	5.44	2.56	1.05	0.00	0.18	0.00
	Earnings	(68.40)	(66.80)	(27.60)	(23.60)	(7.20)	(8.40)	(10.40)	(9.71)	(3.20)	(3.20)
	Cash flow	(201.96)	(183.90)	(86.30)	(30.39)	(15.27)	(12.33)	(8.35)	(9.15)	(4.39)	(3.00)
	Capex	(0.35)	(0.10)	0.02	0.32	0.00	0.00	(0.01)	0.00	0.00	0.00
	Free cash flow	(202.31)	(184.01)	(86.28)	(30.08)	(15.27)	(12.33)	(8.36)	(9.15)	(4.39)	(3.00)
	Book value	(381.00)	(623.39)	(266.24)	(64.73)	(67.97)	(6.22)	(5.59)	(11.84)	2.48	7.65
	Shares, m	0	0	0	1	1	2	2	2	6	8
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00	—
	P/S	75.75	201.83	2.65	18.63	13.66	15.56	27.43	—	77.00	—
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	5.57	—
	EV/Sales	11.96	213.50	3.03	18.48	12.97	12.55	22.12	—	42.82	—
	EV/FCF	(0.16)	(1.39)	(1.40)	(2.24)	(4.69)	(2.64)	(2.78)	—	(1.74)	—
Cash, $m
Cash, $m	Operating cash flow	(48)	(45)	(27)	(23)	(18)	(19)	(16)	(19)	(25)	(25)
	Capex	0	0	0	0	—	—	0	—	—	—
	Free cash flow	(48)	(45)	(27)	(23)	(18)	(19)	(16)	(19)	(25)	(25)
Balance, $m
Balance, $m	Working capital	41	(7)	(15)	(11)	1	7	19	0	33	83
	Total debt	11	15	6	1	1	0	0	—	—	—
	Net debt	(40)	3	5	(2)	(6)	(13)	(12)	(9)	(37)	(89)
	Shareholders’ equity	(91)	(151)	(83)	(49)	(80)	(10)	(11)	(25)	14	64
Returns, %
Returns, %	ROA	(22.40)	(39.18)	(47.43)	(146.36)	(70.66)	(64.51)	(65.28)	(91.51)	(74.92)	(42.09)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	19.36	13.34	7.40	19.78	13.16	28.91	187.15	114.34	355.76	(68.52)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ENGN enGene Therapeutics Inc	$114.6M	— (loss-making)	—	—	n/m	+28.07% (above 0%: growing)	—	0.00%	Compare
SEER Seer, Inc.	$113.0M	— (loss-making)	— (loss-making)	−23.43% (below 0%: shrinking)	n/m	+36.73% (above 0%: growing)	48.55%	(542.91%)	Compare
FHTX Foghorn Therapeutics Inc.	$112.2M	— (loss-making)	— (loss-making)	+112.68% (above 0%: growing)	n/m	+14.88% (above 0%: growing)	100.00%	(54.78%)	Compare
GNLX Genelux Corporation	$112.2M	— (loss-making)	— (loss-making)	—	n/m	−11.18% (below 0%: shrinking)	100.00%	0.00%	Compare
LENZ LENZ Therapeutics, Inc.	$112.2M	— (loss-making)	— (loss-making)	+9.72% (above 0%: growing)	n/m	−229.66% (below 0%: shrinking)	94.90%	(622.89%)	Compare
TNXP Tonix Pharmaceuticals Holding Corp.	$110.1M	— (loss-making)	— (loss-making)	+577.88% (above 0%: growing)	n/m	−178.84% (below 0%: shrinking)	94.81%	(314.05%)	Compare
VTVT vTv Therapeutics Inc.	$109.1M	— (loss-making)	— (loss-making)	+409,222.22% (above 0%: growing)	n/m	−124.59% (below 0%: shrinking)	100.00%	0.00%
CYTT Cyteir Therapeutics, Inc.	$108.7M	— (loss-making)	—	—	n/m	+63.78% (above 0%: growing)	0.00%	0.00%	Compare
INO Inovio Pharmaceuticals, Inc.	$107.5M	— (loss-making)	— (loss-making)	−83.19% (below 0%: shrinking)	n/m	+13.41% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$112.2M	—	—	+9.72%	—	+14.15%	94.90%	(27.39%)

All 614 Biotechnology stocks →

vTv Therapeutics Inc. (VTVT) key facts

vTv Therapeutics Inc. (VTVT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VTVT traded at $26.54, a market capitalization of $109.1 million.
Return on equity was −68.5% and debt-to-equity 0.00.
Its Altman Z-score is −10.00 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.